Patrys (ASX:PAB)
ASX announcement history & article coverage
Transparent by design.
Announcments by Patrys (ASX:PAB) are listed here, whether we covered it or not. Where we've written an article, you'll see it linked directly. Where we haven't, the filing is still shown so nothing is hidden from view. If you think a particular announcement deserved editorial coverage and was overlooked, you can flag it for review and our team will take a look.
Appendix 4E - Preliminary Final Report
Ethics Approval Secured for Phase 1A Clinical Trial
Patrys secures ethics approval for Phase 1A clinical trial of RLS-2202, dosing to start this quarter
Investor Presentation - TechKnow Invest Roadshow
Patrys advances injectable quetiapine for delirium with accelerated FDA pathway and strong IP protection
Appendix 4C - Quarterly - 30 June 2026
Cleansing Notice
Notification regarding unquoted securities - PAB
Application for quotation of securities - PAB
Patrys Secures 50% Revenue Share in IP Commercialisation
Patrys Secures 50% Revenue Share in Deoxymab IP Commercialisation Deal with Yale University
Becoming a substantial holder
Change of Director's Interest Notices x4
Notification regarding unquoted securities - PAB
Cleansing Notice
Application for quotation of securities - PAB
Proposed issue of securities - PAB
Results of Meeting